4Rozenblum E, Schutte M, Goggins M, et al. Tumorsuppressive pathways in pancreatic carcinoma. Cancer Res,1997, 57: 1731-1734.
5Apple SK, Hecht JR, Lewin DN, et al. Immunohistochemical evaluation of K-ras, p53 and HER-2/neu expression in hyperplastic dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol,1999, 30: 123-129.
6Mizumoto K, Tanaka M. Genetic diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Surg, 2002, 9: 39-44.
7Ha A, Watanabe H, Yamaguchi Y, et al. Usefulness of supernatant of pancreatic juice for genetic analysis of K-ras in diagnosis of pancreatic carcinoma. Pancreas, 2001, 23: 356-363.
8Kimura W, Zhao B, Futakawa N, et al. Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas. Hepatogastroenterology, 1999, 46 :532-539.
9Tateishi K, Tada M, Yamagata M, et al. Hight proportion of mutant K-ras gene in pancreatic juice of patients with pancreatic cystic lesion. Gut, 1999,45:737-740.
10Ruggeri B, Zhang SY, Caamano J, et al. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.Oncogene, 1992, 75 1503-1511.
